<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title xml:lang="ru">Антибиотики и Химиотерапия</journal-title><trans-title-group xml:lang="en"><trans-title>Antibiot Khimioter = Antibiotics and Chemotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0235-2990</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">antibiotics-239</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>В ПОМОЩЬ ПРАКТИКУЮЩЕМУ ВРАЧУ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>GUIDELINES FOR PRACTITIONERS</subject></subj-group></article-categories><title-group><article-title>Инфекционный эндокардит стафилококковой этиологии: клиническое течение и антибактериальная терапия</article-title><trans-title-group xml:lang="en"><trans-title>Infective Endocarditis of Staphylococcal Etiology: Clinical Process and Antibacterial Therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яковлев</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakovlev</surname><given-names>S. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щека</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shcheka</surname><given-names>D. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Суворова</surname><given-names>М. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Suvorova</surname><given-names>M. P.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сергеева</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sergeeva</surname><given-names>E. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черкасова</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Cherkasova</surname><given-names>N. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Московской медицинской академии им. И. М. Сеченова; Городская клиническая больница № 7, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I. M. Sechenov Moscow Medical Academy; Municipal Clinical Hospital No.7, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>13</day><month>05</month><year>2020</year></pub-date><volume>54</volume><issue>5-6</issue><fpage>59</fpage><lpage>64</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Яковлев С.В., Щека Д.В., Суворова М.П., Сергеева Е.В., Черкасова Н.А., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Яковлев С.В., Щека Д.В., Суворова М.П., Сергеева Е.В., Черкасова Н.А.</copyright-holder><copyright-holder xml:lang="en">Yakovlev S.V., Shcheka D.V., Suvorova M.P., Sergeeva E.V., Cherkasova N.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.antibiotics-chemotherapy.ru/jour/article/view/239">https://www.antibiotics-chemotherapy.ru/jour/article/view/239</self-uri><abstract><p>Проанализированы особенности клинического течения и адекватность различных режимов антибиотикотерапии стафилококкового эндокардита у 115 госпитализированных больных (за 10-летний период). Выделены 4 клинических критерия для прогнозирования стафилококковой этиологии эндокардита: внутривенная наркомания, спленомегалия, лейкоцитоз и геморрагическая сыпь на коже. Анализ отечественных и зарубежных данных показал, что адекватной терапией, приводящей к эрадикации возбудителя, в случае оксациллиночувствительных стафилококков являются беталактамы (оксацил-лин, цефалоспорины I и III поколений) и линкомицин, а применение ципрофлоксацина и ванкомицина нецелесообразно; в случае метициллинорезистентных S.aureus (MRSA) рекомендуется ванкомицин, а для лечения эндокардита, вызванного S.aureus с промежуточной устойчивостью к ванкомицину - VISA (МПК выше 0,5 мкг/мл), рекомендуется линезолид.</p></abstract><trans-abstract xml:lang="en"><p>Characteristics of the clinical process of staphylococcal endocarditis in 115 inpatients and the adequacy of various regimens for their antibiotic therapy within a period of 10 years were analysed. Four clinical criteria for prognosis of staphylococcal endocarditis were determined: intravenous narcomania, splenomegalia, leukocytosis and hemorrhagic skin eruption. The analysis of the Russian and foreign findings showed that the use of betalactams (oxacillin, the 1st and 3rd generation cephalosporins) and lincomycin provided the adequate therapy resulting in eradication of the pathogen in case of oxacillin resistant staphylococci, whereas the use of ciprofloxacin and vancomycin was inexpedient. In case of MRSA it was recommended to use vancomycin and in case of endocarditis due to S.aureus with intermediate resistance to vancomycin (VISA, MIC &gt; 0.5 mcg/ml) the use of line-zolid was recommended.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>стафилококковый эндокардит</kwd><kwd>клиника</kwd><kwd>прогнозирование</kwd><kwd>антибиотикотерапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>staphylococcal endocarditis</kwd><kwd>clinical process</kwd><kwd>prognosis</kwd><kwd>antibiotic therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Cabell C. H., Andeson D. V., Buell H. E. et al. The changing face of endocarditis in the 1990s. 40th ICAAC (9/17/2000 through 9/20/2000).</mixed-citation><mixed-citation xml:lang="en">Cabell C. H., Andeson D. V., Buell H. E. et al. The changing face of endocarditis in the 1990s. 40th ICAAC (9/17/2000 through 9/20/2000).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Miro J. M., Anguera I., Cabell C. H. et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis. Clin Infect Dis 2005; 41: 507-514.</mixed-citation><mixed-citation xml:lang="en">Miro J. M., Anguera I., Cabell C. H. et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis. Clin Infect Dis 2005; 41: 507-514.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Николаевский E. H., Хубулава Г. Г., Удальцов Б. Б. Инфекционный эндокардит (современное состояние проблемы): Монография. Самара: 2006. 198.</mixed-citation><mixed-citation xml:lang="en">Николаевский E. H., Хубулава Г. Г., Удальцов Б. Б. Инфекционный эндокардит (современное состояние проблемы): Монография. Самара: 2006. 198.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Drinkovic D., Morris A. J., Pottumarthy S. et al. Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis. J Antimicrob Chemother 2003; 52: 820-825.</mixed-citation><mixed-citation xml:lang="en">Drinkovic D., Morris A. J., Pottumarthy S. et al. Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis. J Antimicrob Chemother 2003; 52: 820-825.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lee S. H., Chung M. H., Lee J. S. et al. A case of Staphylococcus aureus endocarditis after ear piercing in a patient with normal cardiac valve and a questionnaire survey on adverse events of body piercing in college students of Korea. Scand J Infect Dis 2006; 38: 2: 130-132.</mixed-citation><mixed-citation xml:lang="en">Lee S. H., Chung M. H., Lee J. S. et al. A case of Staphylococcus aureus endocarditis after ear piercing in a patient with normal cardiac valve and a questionnaire survey on adverse events of body piercing in college students of Korea. Scand J Infect Dis 2006; 38: 2: 130-132.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Pistella E., Campanile F., Bongiorno D. et al. Successful treatment of disseminated endocarditis unresponsive to vancomycin therapy with linezolid. Scand J Infect Dis 2004; 36 (3): 222-225.</mixed-citation><mixed-citation xml:lang="en">Pistella E., Campanile F., Bongiorno D. et al. Successful treatment of disseminated endocarditis unresponsive to vancomycin therapy with linezolid. Scand J Infect Dis 2004; 36 (3): 222-225.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Белов Б. С. Инфекционный эндокардит II. Особенности течения, критерии диагноза, дифференциальная диагностика. Инфекц антимикроб тер 2004; 4: 120-123.</mixed-citation><mixed-citation xml:lang="en">Белов Б. С. Инфекционный эндокардит II. Особенности течения, критерии диагноза, дифференциальная диагностика. Инфекц антимикроб тер 2004; 4: 120-123.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mandell G. L., Bennett J. E., Dolin R. Principles and practice of infectious diseases. 2000; 857-892.</mixed-citation><mixed-citation xml:lang="en">Mandell G. L., Bennett J. E., Dolin R. Principles and practice of infectious diseases. 2000; 857-892.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Petti C. A., Fowler V. G. Jr. Staphylococcus aureus bacteriemia and endocarditis. Infect Dis Clin North Am 2002; 16: 413.</mixed-citation><mixed-citation xml:lang="en">Petti C. A., Fowler V. G. Jr. Staphylococcus aureus bacteriemia and endocarditis. Infect Dis Clin North Am 2002; 16: 413.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Le T., Bayer A. S. Combination antibiotic therapy for infective endocarditis. Clin Infect Dis 2003; 36: 615-621.</mixed-citation><mixed-citation xml:lang="en">Le T., Bayer A. S. Combination antibiotic therapy for infective endocarditis. Clin Infect Dis 2003; 36: 615-621.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Тюрин В. П. Острый инфекционный эндокардит: тактика ведения и лечения. Сердце 2003; 5: 226-230.</mixed-citation><mixed-citation xml:lang="en">Тюрин В. П. Острый инфекционный эндокардит: тактика ведения и лечения. Сердце 2003; 5: 226-230.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Белобородов В. Б. Инфекционный эндокардит. Стратегия выбора антибактериальной терапии. Сердце 2003; 5: 242-247.</mixed-citation><mixed-citation xml:lang="en">Белобородов В. Б. Инфекционный эндокардит. Стратегия выбора антибактериальной терапии. Сердце 2003; 5: 242-247.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Белов Б. С. Инфекционный эндокардит III. Лечение и профилактика. Инфекц антимикроб тер 2004; 5: 149-154.</mixed-citation><mixed-citation xml:lang="en">Белов Б. С. Инфекционный эндокардит III. Лечение и профилактика. Инфекц антимикроб тер 2004; 5: 149-154.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Fortun J., Navas E., Martinez-Beltran J. et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001; 33: 120-125.</mixed-citation><mixed-citation xml:lang="en">Fortun J., Navas E., Martinez-Beltran J. et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001; 33: 120-125.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Jones R. N. Key considerations in the treatment of complicated staphylococcal infections. Clin Microbiol Infect 2008; 14: Suppl 2: 3-9.</mixed-citation><mixed-citation xml:lang="en">Jones R. N. Key considerations in the treatment of complicated staphylococcal infections. Clin Microbiol Infect 2008; 14: Suppl 2: 3-9.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Sakoulas G., Moise-Broder P., Schentag G. et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteriemia. J Clin Microbiol 2004; 42: 6: 2398-2402.</mixed-citation><mixed-citation xml:lang="en">Sakoulas G., Moise-Broder P., Schentag G. et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteriemia. J Clin Microbiol 2004; 42: 6: 2398-2402.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Soriano A., Marco F., Martinez J. et al. Influence of vancomycin minimum inhibitory concentrations on the treatment of methicillin-resistant Staphylococcus aureus bacteriemia. Clin Infect Dis 2008; 46: 193-200.</mixed-citation><mixed-citation xml:lang="en">Soriano A., Marco F., Martinez J. et al. Influence of vancomycin minimum inhibitory concentrations on the treatment of methicillin-resistant Staphylococcus aureus bacteriemia. Clin Infect Dis 2008; 46: 193-200.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Neoh H., Hori S., Komatsu M. et al. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann Clin Microbiol Antimicrob 2007; 6: 13: 1-6.</mixed-citation><mixed-citation xml:lang="en">Neoh H., Hori S., Komatsu M. et al. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann Clin Microbiol Antimicrob 2007; 6: 13: 1-6.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">DiNubile M. J. Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users. Clin Infect Dis 2001; 33: 120-125.</mixed-citation><mixed-citation xml:lang="en">DiNubile M. J. Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users. Clin Infect Dis 2001; 33: 120-125.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tsagonis T., Skiadas I., Koutoukas P. et al. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis.</mixed-citation><mixed-citation xml:lang="en">Tsagonis T., Skiadas I., Koutoukas P. et al. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Jacqueline C., Batard E., Perez I. et al. In vivo efficacy of continious infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob Agents Chemother 2002; 46: 3706-3711.</mixed-citation><mixed-citation xml:lang="en">Jacqueline C., Batard E., Perez I. et al. In vivo efficacy of continious infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob Agents Chemother 2002; 46: 3706-3711.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Munoz P., Rodriguez-Creixems M., Moreno M. et al. Linezolid therapy for infectious endocarditis. Clin Microbiol Infect 2007; 13: 211-215.</mixed-citation><mixed-citation xml:lang="en">Munoz P., Rodriguez-Creixems M., Moreno M. et al. Linezolid therapy for infectious endocarditis. Clin Microbiol Infect 2007; 13: 211-215.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Falagas M. E., Manta K. G., Ntziora F. et al. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 2006; 58: 273-280.</mixed-citation><mixed-citation xml:lang="en">Falagas M. E., Manta K. G., Ntziora F. et al. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 2006; 58: 273-280.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Белобородова H. В., Кузнецова С. Т., Вострикова Т. Ю. и др. Первый опыт клинического применения нового антибиотика линезолида в кардиохирургии. Антибиотики и химиотер 2003; 48: 8: 11-16.</mixed-citation><mixed-citation xml:lang="en">Белобородова H. В., Кузнецова С. Т., Вострикова Т. Ю. и др. Первый опыт клинического применения нового антибиотика линезолида в кардиохирургии. Антибиотики и химиотер 2003; 48: 8: 11-16.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Белобородова Н. В., Седракян А. Р. Место линезолида в лечении инфекционного эндокардита. Инфекции и антимикробная терапия 2008; Альманах «Инфекции в стационаре», 6-10.</mixed-citation><mixed-citation xml:lang="en">Белобородова Н. В., Седракян А. Р. Место линезолида в лечении инфекционного эндокардита. Инфекции и антимикробная терапия 2008; Альманах «Инфекции в стационаре», 6-10.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Falagas M. E., Matthaiou D. K., Bliziotis I. The role of aminoglycosides in combination with beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 2006; 57: 639-647.</mixed-citation><mixed-citation xml:lang="en">Falagas M. E., Matthaiou D. K., Bliziotis I. The role of aminoglycosides in combination with beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 2006; 57: 639-647.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
